Roland Honeine, MD
Allergy · Orchard Park, NYNPI 1285817841
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,578 of the $3,937 with a category attached, or 65.5%. 16 manufacturers reported payments, led by Sanofi at 45.9% of the total. Reporting peaked in 2019 at $2,322 and has fallen 88.3% since, to $272 in 2025.
Across 46 payments — averaging $85.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- GSK$618
- Genentech USA, Inc.$365
- Regeneron Healthcare Solutions, Inc.$171
- Takeda Pharmaceuticals U.S.A., Inc.$125
- Teva Pharmaceuticals USA, Inc.$125
- plus $726 from 10 others
What the payments were for
- Consulting fees$1,31633%
- Travel & lodging$130%
- Food & beverage$2,57865%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 7 | $1,806 |
| GSK | 20 | $618 |
| Genentech USA, Inc. | 3 | $365 |
| Regeneron Healthcare Solutions, Inc. | 3 | $171 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $125 |
| Shire North American Group Inc | 1 | $119 |
| AstraZeneca | 1 | $110 |
| Incyte Corporation | 1 | $97 |
| Optinose US, Inc. | 1 | $89 |
| Pharming Healthcare, Inc. | 1 | $81 |
| Kaleo, Inc. | 2 | $30 |
| Boehringer Ingelheim | 1 | $30 |
| Hikma Pharmaceuticals USA | 1 | $23 |
| Galderma Laboratories, L.p. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,937 in reported general payments places this provider in the 65th percentile of 92 allergy providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 21 | $76,870 |
| Dupixent PenDupilumab | 12 | $49,173 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $44,574 |
| Breo ElliptaFluticasone/Vilanterol | 65 | $29,972 |
| Spiriva RespimatTiotropium Bromide | 28 | $18,952 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 76 | $14,579 |
| Epinephrine | 34 | $10,410 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 34 | $7,938 |
| Azelastine Hcl | 224 | $5,259 |
| Qvar RedihalerBeclomethasone Dipropionate | 20 | $5,213 |
| Fluticasone Propionate HfaFluticasone Propionate | 18 | $4,697 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,557 |
| Arnuity ElliptaFluticasone Furoate | 16 | $3,525 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 90 | $3,443 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 21 | $2,905 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $618 | $154,941152 claims |
| Boehringer IngelheimSpiriva Respimat | $30 | $18,95228 claims |
| Hikma Pharmaceuticals USAEpinephrine | $23 | $10,41034 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $125 | $5,21320 claims |
| AstraZenecaSymbicort | $110 | $4,55713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 92 allergy providers in New York.
Other allergy in Orchard Park
- Andrew GreenOrchard Park$2K
- Maria LennoxOrchard Park$811
- Marc BraunsteinHewlett$884K
- Allison RamseyRochester$643K
- Christopher SmithHorseheads$622K
- Anne MaitlandTarrytown$292K
- Yudhistira PersaudBronx$127K
- Michael KatlanAlbany$91K
- Michel AklJamestown$90K
- Juan SotomayorNorth Syracuse$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.